Talecris Company Description
Talecris Biotherapeutics Holdings taps into the healing power of blood. The biopharmaceutical company develops protein therapy products (derived from blood plasma) used to treat conditions such as immune deficiency disorders, severe burns, and hemophilia. The plasma proteins help control bleeding and body function, as well as combat infection. Its lead product, Gamunex IGIV, helps in the treatment of immune deficiency conditions and leukemia, and with bone marrow transplant recovery. Its Prolastin product is used to treat emphysema. Talecris Biotherapeutics operates worldwide from offices in North America and Germany. Cerberus Capital Management controls the company.
View the Comprehensive Company Description for Talecris
The Company Description provides a historical perspective of Talecris's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Talecris's evolution in the marketplace.
